Previous Article | Next Article 
Journal of Virology, December 2001, p. 12028-12038, Vol. 75, No. 24
Department of Microbiology, Immunology & Molecular
Genetics, UCLA School of Medicine1 and
UCLA AIDS Institute,2 Los Angeles,
California 90095; Department of Microbiology, University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania
191043; and Medical Research Council
Cancer Cell Unit, Hutchison/MRC Research Center, Cambridge CB2 2XZ,
United Kingdom4
Received 24 July 2001/Accepted 18 September 2001
DC-SIGN is a C-type lectin expressed on dendritic cells and
restricted macrophage populations in vivo that binds gp120 and acts in
trans to enable efficient infection of T cells by human immunodeficiency virus type 1 (HIV-1). We report here that DC-SIGN, when expressed in cis with CD4 and coreceptors, allowed
more efficient infection by both HIV and simian immunodeficiency virus
(SIV) strains, although the extent varied from 2- to 40-fold, depending on the virus strain. Expression of DC-SIGN on target cells did not
alleviate the requirement for CD4 or coreceptor for viral entry. Stable
expression of DC-SIGN on multiple lymphoid lines enabled more efficient
entry and replication of R5X4 and X4 viruses. Thus, 10- and 100-fold
less 89.6 (R5/X4) and NL4-3 (X4), respectively, were required to
achieve productive replication in DC-SIGN-transduced Jurkat cells when
compared to the parental cell line. In addition, DC-SIGN expression on
T-cell lines that express very low levels of CCR5 enabled entry and
replication of R5 viruses in a CCR5-dependent manner, a property not
exhibited by the parental cell lines. Therefore, DC-SIGN expression can
boost virus infection in cis and can expand viral
tropism without affecting coreceptor preference. In addition, coexpression of DC-SIGN enabled some viruses to use alternate coreceptors like STRL33 to infect cells, whereas in its absence, infection was not observed. Immunohistochemical and confocal microscopy data indicated that DC-SIGN was coexpressed and colocalized with CD4
and CCR5 on alveolar macrophages, underscoring the physiological significance of these cis enhancement effects.
Enveloped viral entry is mediated by
interactions between cell surface receptor(s) and the viral envelope
(Env) embedded in the virion lipid bilayer. These interactions trigger
the requisite conformational changes in the viral Env that eventually
lead to fusion between the viral and host cell membranes and delivery of the viral genome into the target cell. Human immunodeficiency virus
type 1 (HIV-1) has evolved to use the CD4-coreceptor complex to trigger
the conformational events leading to membrane fusion (reviewed in
reference 8). In addition to entry receptors, attachment
receptors have been described that can modulate the efficiency of entry
mediated by the CD4-coreceptor complex (reviewed in reference
37). For example, heparan sulfate proteoglycans (21,
24, 29) and LFA-1 (12) have been reported to
interact with viral Env or virion-associated adhesion molecules such as ICAM-1 in a manner that enhances the viral entry process. However, the
majority of these interactions are low affinity in nature, having
binding constants of 500 nM or greater (36, 37). Unique among these attachment molecules is the calcium-dependent lectin DC-SIGN, which binds to monomeric HIV-1 gp120 with a greater
affinity than CD4 (Kd, 1.4 nM versus 4 to
5 nM for CD4) (6). The binding of DC-SIGN to HIV Env is
carbohydrate dependent and is most effectively competed off by mannan
(6, 13, 27).
DC-SIGN is a type II integral membrane protein originally cloned from a
placental cDNA library as a gp120 binding protein (6). It
is highly expressed on dendritic cells (DCs) and is largely responsible
for HIV-1 attachment to this cell type (13, 14). A homolog
of DC-SIGN, termed "DC-SIGNR/L-SIGN," is expressed on some types of
endothelial cells and also serves as a virus attachment factor
(3, 28, 33). Virus bound to DC-SIGN-positive cells can be
transmitted to cells expressing CD4 and coreceptor, resulting in
efficient virus infection in trans (13, 27). DC-SIGN on DCs may serve as a conduit for the transfer of HIV-1 from
the submucosa to permissive T cells in secondary lymphoid organs
(13, 35). We have shown that DC-SIGN also binds HIV-2 and
SIV Envs and thus can be considered a universal attachment factor for
primate lentiviruses (27). Despite initial reports that
DC-SIGN expression is restricted to DCs, we have found that DC-SIGN is
expressed on CD4+ macrophages in the placenta and
lung (34; E. Soilleux, L. S. Morris, G. Leslie et
al., submitted for publication). The presence of such a high-affinity
attachment molecule on permissive cells in vivo prompted us to examine
the consequences of DC-SIGN expression on the efficiency of viral entry.
We found that expression of DC-SIGN in cis with CD4 and
coreceptor allowed for more efficient entry of HIV and SIV. The ability of DC-SIGN to facilitate infection in cis was most apparent
when either CD4 or coreceptor was limiting. In some cases, DC-SIGN expression allowed infection of cells via CD4 and an alternate coreceptor (STRL33) that is otherwise used inefficiently
(30). In addition, some T-cell lines engineered to express
DC-SIGN required up to 100-fold less of the viral inoculum in order to
establish a productive infection. The in vivo significance of this
cis-enhancement effect was supported by confocal microscopy
data indicating that DC-SIGN was expressed and colocalized with CD4 and
CCR5 on primary alveolar macrophages. Thus, DC-SIGN expression or
upregulation in vivo can potentially expand viral tropism by allowing
viruses to infect cells with limiting amounts of CD4 or coreceptor or by more efficient use of alternative coreceptors.
Viruses and cells.
DC-SIGN was cloned into the retroviral
MIGR1 vector (a kind gift from Warren Pear, University of Pennsylvania)
via the HpaI and BamHI site. Expression of
DC-SIGN was mediated by the MSCV long terminal repeat promoter and
green fluorescent protein (GFP) was expressed in tandem via an internal
ribosome entry site (IRES) linker. Retroviruses expressing DC-SIGN were
made by cotransfecting HEK 293T producer cells with MIGR1-DC-SIGN,
pcGP (expressing gag and pol genes) and pVSV-G
(expressing the vesicular stomatitis virus [VSV]-G envelope
glycoprotein) by using Geneporter. Forty-eight hours after
transfection, the retroviral supernatant was filtered through a
0.22-µm-pore-size filter and stored at Infections.
Equal number of cells from DC-SIGN-transduced
cell lines or the parental lines (2 × 105
to 5 × 105 cells/infection) were infected
with the indicated amount of viral supernatant. Four hours after
infection, cells were washed three times vigorously with 1×
phosphate-buffered saline (PBS), and the medium was replaced. For
measurement of p24 antigen production, infections were performed in 96 wells in a total volume of 200 µl. On the indicated days after
infection, medium was half-exchanged with fresh medium, and the
supernatant was stored at Measurement of cell-associated viral DNA.
Cell-associated
DNA was prepared from 105 infected CEM-SS cells,
by lysis in 100 µl of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.2 mM
CaCl2, 0.001% Triton X-100, 0.001% sodium
dodecyl sulfate (SDS), 1 µg of proteinase K per ml. The lysates were
then incubated at 58°C overnight, heat inactivated at 95°C for 15 min, and stored at
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.24.12028-12038.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
cis Expression of DC-SIGN Allows for
More Efficient Entry of Human and Simian Immunodeficiency Viruses
via CD4 and a Coreceptor
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
80°C. Retroviral transduction of the indicated cell lines was performed by spinoculation as described previously (23). All cell lines were
originally obtained from the American Tissue Type Collection (ATCC).
One week after spinoculation, cell lines were sorted for GFP-positive cells to select for stably transduced cells. GFP-positive cell lines
were confirmed to be expressing DC-SIGN by costaining with a monoclonal
antibody (MAb) against DC-SIGN (MAb 28) (2a). Pseudotyped GFP or luciferase reporter viruses were made as previously described (30).
20°C. p24 levels in viral supernatants
from the same infection series were analyzed together with a commercial
enzyme-linked immunosorbent assay (ELISA) kit. For inhibition
experiments, cells were infected as described above or in the presence
of an anti-CXCR4 MAb (20 µg of MAb 45701 per ml; R&D Systems,
Minneapolis, Minn.) or an anti-CD4 MAb (10 µg of Leu3A per ml), or
TAK779 (20 µM; a kind gift from Takeda Pharmaceuticals, Osaka,
Japan). Four hours after infection, cells were washed three times
vigorously with 1× PBS and the medium was replaced with fresh medium
containing the inhibitory reagents as indicated above. On the indicated
days after infection, the medium was half-exchanged with fresh medium
containing fresh inhibitory reagents as described above. Pseudotyped
virus infection was performed as described above, except that analysis
was performed 3 days postinfection. The extent of infection was
quantified either by fluorescence-activated cell sorter (FACS) analysis
of GFP-positive cells or of p24-positive cells (determined by
intracellular p24 staining with phycoerythrin-conjugated anti-p24 KC57
clone from Coulter) as previously described (30). For
mannan inhibition, infections were performed as described above in the
presence of 100 µg of mannan per ml (Sigma).
80°C. Kinetic (fluorescence monitored) PCR was
performed with 1.25 × 104 cell equivalents
to quantitate viral gag DNA and cellular 
-globin DNA. The
sequences of the -globin forward and reverse primers and the
molecular beacon were 5'-CCCTTGGACCCAGAGGTTCT-3' and
5'-CGAGCACTTTCTTGCCATGA-3' and
GCGAGCATCTGTCCACTCCTGATGCTGTTATGGGCGCTCGC-3', respectively. The
molecular beacon was labeled with JOE
(6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein) and DABCYL, at
the 5' and 3' ends, respectively. The sequences of the gag
forward and reverse primers and TaqMan probe were
5'-AAGCAGCAGCTGACACAGGA-3', 5'-TTTGCCCCTGGATGTTCTG-3', and
5'-ACAGCAATCAGGTCAGCCAAAATTACCCTATAGT-3', respectively. The
TaqMan probe was labeled at the 5' end with FAM (fluorochrome
6-carboxyfluorescein) and at the 3' end with TAMARA
(6-carboxy-N',N',N',N'-tetramethylrhodamine).
Reactions were individually optimized and carried out in 50-µl
volumes containing the following: 50 mM KCl; 10 mM Tris-HCl (pH 8.3); 3 (-globin) to 5.5 (gag) mM MgCl2;
200 (-globin) to 300 (gag) µM dATP, dCTP, dGTP, and
dTTP; 200 (gag) to 1,000 (-globin) nM primer; 200 nM probe; 0.025 U of AmpliTaq Gold (PE BioSystems) per µl; and 500 nM
carboxy-X-rhodamine (Rox) as a passive reference (Molecular Probes,
Eugene, Oreg.). The reaction times and temperatures were 10 min at
95°C and then 40 cycles of 15 s at 95°C and 45 s at 60°C.
-globin
was generated by preparing DNA lysate from uninfected CEM-SS cells that
had been counted with a hemacytometer. These cell counts were then used
to design serial dilutions of DNA lysate in 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, and 1 ng of poly(rA) per ml. Sequence Detection software,
version 3 (PE BioSystems), was used to analyze the kinetic PCR
amplification data.
Selecting and obtaining tissue and tissue processing.
All
tissues were obtained with Local Research Ethics Committee approval.
Fully anonymized histologically normal spleen, lymph node, lung, liver,
and placenta of 12 and 40 weeks of gestation was obtained from the
Department of Histopathology, Addenbrooke's Hospital, Cambridge,
United Kingdom. Tissue was either snap-frozen and kept at 80°C
before being processed to cryosections, or was fixed in 10% neutral
buffered formalin, followed by paraffin wax embedding and sectioning.
Single immunostaining of paraffin sections. Sections were immunostained with rabbit anti-DC-SIGN polyclonal serum, with preimmune serum on serial sections as a negative control, exactly as described previously (34). Further serial sections were immunostained with anti-CD14 (Novocastra, Newcastle upon Tyne, United Kingdom) as previously described (34).
Staining of frozen sections for confocal microscopy. Ten-micrometer cryosections of lung and placenta were fixed for 5 min in 4% paraformaldehyde and then immunostained with mouse monoclonal anti-CD4 (PharMingen, San Diego, Calif.), mouse monoclonal anti-CCR5 (clone CTC5; R&D Systems, Minneapolis, Minn.) or rabbit polyclonal anti-DC-SIGN (34). Each mouse MAb was also used in double immunostaining in combination with rabbit polyclonal anti-DC-SIGN. Primary antibody was added in 1% bovine serum albumin-10% goat serum-10% swine serum in Tris-buffered saline (TBS). Following overnight incubation, sections were rinsed thoroughly in TBS and incubated for 1 h with secondary antibody, which was phycoerythrin-conjugated goat anti-mouse antibody (Sigma, Poole, United Kingdom) and/or fluorescein isothiocyanate (FITC)-conjugated swine anti-rabbit antibody (Dako, Glostrop, Denmark). Sections were rinsed in TBS and mounted in fluorescence mounting medium (Dako, Glostrop, Denmark). As a negative control for the anti-DC-SIGN antiserum, preimmune rabbit serum was used to immunostain serial sections. For the mouse MAbs, the primary antibody was omitted from the negative control slides.
Confocal microscopy. Images were obtained by using a confocal laser scanning microscope TCS 4D (Leica Lasertechnik, Heidelberg, Germany). All double immunostaining was photographed with sequential scanning techniques.
DC-SIGN-CD4-CCR5 coimmunoprecipitation. 293T cells that stably express CCR5 and CD4 were transfected with pcDNA3-DC-SIGN or a red fluorescent protein (Clontech, Palo Alto, Calif.) (negative control) expression plasmid. Cells were washed three times with cold 1× PBS and divided into two aliquots prior to lysis. One aliquot was lysed in 1 ml of Triton X buffer (300 mM NaCl, 50 mM Tris [pH 7.6], 10% glycerol, 0.5% Triton X, and EDTA-free protease inhibitor from Sigma) at room temperature for 30 min while rocking. The other aliquot was lysed in 1 ml of CHAPSO-based buffer (20 mM Tris [pH 7.5], 100 mM ammonium sulfate, 10% glycerol, 1% CHAPSO, and EDTA-free protease inhibitor from Sigma) at 4°C for 30 min while rotating. The cell debris was settled by centrifuging the samples for 10 min at 14,000 rpm. One hundred microliters of lysate, 2.5 µl of 2 M calcium chloride, 8 µl of antibody, and 50 µl of protein G beads (Pierce) were added to 500 µl of either CHAPSO buffer or Triton X buffer. All samples were rotated overnight at 4°C and run on and SDS-polyacrylamide gel electrophoresis (PAGE) gel. Samples were then blotted for CD4 with rabbit anti-CD4 polyclonal antibodies (previously generated by immunizing New Zealand White rabbits with the recombinant soluble 4 domain, CD4) or a mouse MAb against CCR5 (CTC5; R&D Systems, Minneapolis, Minn.). All lysates were blotted individually for DC-SIGN, CD4, and CCR5 to confirm appropriate expression.
QFACS analysis. For quantitative FACS (QFACS) analysis, DC-SIGN expression on stably transduced cell lines was quantified as previously described (18, 27), with the exception that a MAb against DC-SIGN (DC028) (2a) was used instead of an anti-AU1 antibody against AU1-tagged DC-SIGN. Since the same secondary reagent was used in this study (phycoerythrin-conjugated Fab goat anti-mouse from Caltag, Burlingame, Calif.), the levels of DC-SIGN quantified can be reasonably compared. However, the confidence in the absolute number of antibody binding sites obtained would not be as great as that obtained with a directly conjugated primary antibody.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
cis expression of DC-SIGN enhances viral
infection.
The presence of viral attachment molecules on
permissive cells may affect the efficiency of viral entry
(37). Since we recently found that DC-SIGN is expressed
not only on DCs, but also on CD4+ macrophages in
the placenta and lung (34; E. Soilleux, L. S. Morris,
G. Leslie et al., submitted for publication), we sought to examine the
consequences of DC-SIGN expression on infection efficiency. Using
transfected 293T cells expressing high levels of CD4 and coreceptor, we
found that cis expression of DC-SIGN reproducibly enhanced
HIV-1 and SIV infection by two- to threefold (Fig.
1A). This cis enhancement was
specific to HIV-1 and SIV Envs, because infection by murine leukemia
virus (MLV) pseudotypes was not affected by the presence of DC-SIGN.
Since cell surface densities of CD4 and CCR5 can affect significantly
the efficiency of viral entry (26, 30), we sought to
determine if the DC-SIGN enhancement effect was more prominent when
CCR5 levels were reduced. Indeed, when target cells were transfected
with 50-fold less CCR5 expression plasmid than the experiment indicated
above, the presence of DC-SIGN was able to enhance R5 HIV-1 and SIV
entry by more than 10-fold (Fig. 1B), even though the absolute amount
of virus entering these cells was considerably less (compare Fig. 1A
and B). Thus, coexpression of DC-SIGN along with CD4 and an appropriate coreceptor enhances virus infection, particularly when CCR5 levels are
limiting for virus entry.
|
DC-SIGN expression in T-cell lines enhances virus replication.
In order to examine the effect of DC-SIGN cis enhancement on
more relevant cells types, a variety of T-cell lines were transduced with a murine stem cell retrovirus vector (MIGR1-DC-SIGN-GFP) expressing DC-SIGN in tandem with GFP via an IRES linker. We have previously shown that most T-cell lines commonly used to propagate HIV
express tens of thousands of CD4 and CXCR4 molecules per cell, with the
exception of Jurkat cells, which express less than a thousand CD4
molecules per cell (18). Jurkat cells also express less
than 1,000 copies of CCR5 per cell, but do express high levels of CXCR4
(18). Therefore, we hypothesized that the effect of DC-SIGN enhancement might be most pronounced in this cell line. Indeed,
we found that for a given viral inoculum, DC-SIGN-transduced Jurkat
cells supported faster viral replication kinetics for both an X4
(NL4-3) and an R5X4 (89.6) viral strain (Fig.
2A and B, respectively). In addition, up
to 100-fold less virus (NL4-3) was required for productive replication
in DC-SIGN-transduced Jurkat cells (Fig. 2A). Replication of HIV-1
NL4-3 was also modestly enhanced (two- to fivefold increase in peak
p24 antigen values) when DC-SIGN was expressed in SupT1, Molt4 Clone8,
and PM1 cells (data not shown), all of which express high levels of CD4
and CXCR4 (18). Therefore, DC-SIGN expression enhances
CXCR4-dependent virus replication in several T-cell lines, with its
effects being more pronounced when CD4 expression levels are limiting.
|
|
Increased viral replication in DC-SIGN-transduced cell lines is due
to enhanced viral entry and is CD4 dependent.
We have previously
shown that virus adsorption onto cells is markedly enhanced in the
presence of DC-SIGN (27, 28). However, in order to
determine if DC-SIGN-enhanced viral replication is due to more
efficient viral entry, a quantitative real-time PCR assay for
reverse-transcribed products was performed at 20 h postinfection. With the same amount of viral inoculum, we found that there was a
significant increase in the number of viral gag DNA copies
per cell (represented by the gag/-globin ratio) in various
DC-SIGN-transduced cell lines when compared to their respective
parental lines during the first round of infection (Fig.
4A). DC-SIGN-enhanced viral entry was CD4
dependent, because the gag/-globin ratio was reduced from 8.0 to
0.13 in the presence of Leu3a, a neutralizing anti-CD4 antibody (Fig.
4B). Thus, DC-SIGN itself cannot mediate entry in the absence of CD4,
consistent with previous reports (13), and its enhancement
effects are at the level of virus entry.
|
cis enhancement of viral infection via alternate
coreceptors.
Alternate coreceptors such as STRL33 tend to support
virus infection less efficiently than CCR5 and CXCR4. We have shown
that STRL33 is expressed on some CD4+ T cells at
levels (<10,000 molecules per cell) below that needed to support
efficient entry for most virus strains (30). Therefore, we
determined whether DC-SIGN could enhance infection when coexpressed with this alternate coreceptor. By using cells expressing STRL33 at
levels previously determined to result in little or no infection by
either SIV or HIV Env pseudotypes (30), we found that
expression of DC-SIGN-enhanced virus infection between 2- and 40-fold,
depending on the viral Env used (Fig. 5A
and B). Infection by VSV pseudotypes was not affected by the presence
of DC-SIGN (Fig. 5B). A similar level of enhancement was obtained when
luciferase rather than GFP reporter viruses were used (data not shown).
Thus, the ability of DC-SIGN to enhance viral infection when expressed
in cis extends to coreceptors other than CCR5 and CXCR4.
|
DC-SIGN is expressed on permissive CD4+ CCR5+ cells in situ Since DC-SIGN can enhance viral entry on permissive cells expressing low levels of CD4 or coreceptor, we sought to obtain evidence of DC-SIGN expression on such candidate permissive cells in vivo. We have previously shown that DC-SIGN is expressed on both maternal decidual macrophages and fetal Hofbauer cells in human placenta (34) and on some human alveolar macrophages (E. Soilleux, L. S. Morris, G. Leslie et al., submitted for publication). Both alveolar and placental tissue macrophages have been reported to express very low levels of CD4 and to be targets for HIV infection in vivo (16, 17, 20, 22, 25, 31). In the case of SIV, macrophage tropism is often associated with changes in the viral Env protein that either make it CD4 independent or better able to infect cells that express low levels of CD4 (2, 22; B. Puffer, S. Pohlmann, A. L. Edinger et al., submitted for publication). Therefore, DC-SIGN expression may contribute to the establishment of a viral reservoir in these cells by allowing more efficient entry.
Accordingly, we performed immunohistochemistry on various tissues to determine if DC-SIGN was expressed on other macrophage populations in situ. We found that while CD14+ macrophages from lymph node, spleen, and liver were DC-SIGN negative (data not shown) (Fig. 6A), DC-SIGN expression could clearly be detected on placental, decidual, and alveolar macrophages (34) (Fig. 6A). It is known that alveolar macrophages are heterogeneous with regard to their morphology, immunophenotype (CD14 expression), and function (15, 39), and we note that DC-SIGN was only coexpressed with a subset of CD14low alveolar macrophages (Fig. 6A). Strikingly, when confocal microscopy was performed on alveolar macrophages to determine coexpression of CCR5 and CD4 with DC-SIGN, we found physical colocalization of DC-SIGN and CCR5, and, to a lesser extent, CD4 (Fig. 6B). In Fig. 6B, essentially 100% of CCR5+ membrane areas (red) were also positive for DC-SIGN (yellow overlap). The physical colocalization of DC-SIGN with CCR5 and CD4 may in part explain the cis enhancement effect of DC-SIGN. However, we were unable to determine that DC-SIGN is physically associated with CCR5 or CD4 in coimmunoprecipitation experiments in transiently transfected cells, at least under the conditions examined (see Materials and Methods) (data not shown).
|
.
(Alveoli) DC-SIGN-positive cells in the alveoli also express low levels
of CD14 (arrows in right and left panels point to cells staining for
both markers). Alveolar macrophages are a heterogeneous population and
can vary in their amount of CD14 expression. DC-SIGN-positive cells in
the alveoli appear to be restricted to CD14low cells
(arrows). (B) Confocal microscopy performed on alveolar macrophages
showing expression of DC-SIGN (red) with CCR5 (green) and CD4 (green).
Note the almost complete colocalization of DC-SIGN with CCR5 (yellow
overlap).
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
Binding of the HIV-1 Env protein to CD4 and a coreceptor is required for virus entry. However, attachment of virus to the cell surface can occur via low-affinity interactions with a relatively large number of cellular molecules (reviewed in reference 37). By concentrating virus on the cell surface, attachment factors may make subsequent receptor engagement more efficient. Among attachment factors, the C-type lectin DC-SIGN is unusual in that it binds to gp120 with very high affinity (6) and is particularly efficient at retaining bound virus in an infectious state for prolonged periods of time and in presenting bound virus to receptor-positive cells in trans (13). Because DC-SIGN is expressed at high levels on some types of DCs, it has been suggested that HIV-1 may bind to DCs via DC-SIGN and, through the normal trafficking patterns of this antigen-presenting cell, be delivered to lymphoid organs that serve as the major site for virus replication in vivo (13).
We have found that DC-SIGN is expressed on certain types of macrophages in vivo, including macrophages in human placenta (34) and alveolar macrophages (Fig. 6A) (E. Soilleux, L. S. Morris, G. Leslie et al., submitted for publication), In addition, DC-SIGN expression can be induced on monocyte-derived macrophages by treatment with interleukin 13, raising the possibility that DC-SIGN may sometimes be expressed on additional cell types in vivo that can support virus replication (Soilleux et al., submitted). Therefore, it becomes important to determine if the presence of this efficient virus attachment factor on macrophages impacts virus entry not only in trans, but in cis as well.
We found that DC-SIGN expression in cis enhanced the efficiency of virus infection, especially when CD4 and coreceptor levels were limiting. The ability of DC-SIGN to allow R5 viral infection of T-cell lines such as Jurkat and SupT1 cells was particularly notable, since these cells express vanishingly small amounts of surface CCR5 (18) and are otherwise refractory to R5 virus entry (5, 7). This finding also shows that expression of DC-SIGN in cis can, in effect, change viral tropism without affecting coreceptor usage. The ability of DC-SIGN, and perhaps other attachment factors as well, to enhance virus infection in cis when receptor levels are limiting may not be appreciated, since cell lines commonly used to assess which coreceptors are used by a given virus strain typically express tens of thousands of CD4 and coreceptor molecules (18). In contrast, receptor levels on primary cell types are often much lower. For example, freshly isolated primary CD4+ lymphocytes generally have less than 10,000 CCR5 and CXCR4 antibody binding sites per cell (18). Therefore, the ability of DC-SIGN to enhance virus infection in cis demonstrates that attachment factors can help virus infect cells under coreceptor-limiting conditions.
We also found that DC-SIGN can enhance virus infection in cis when CD4 expression levels are low. In vivo, CD4 levels can be limiting for virus infection under some conditions, especially on some types of tissue macrophages. Alveolar macrophages, for example, express very low levels of CD4 (2, 19, 22). Interestingly, we found that a significant fraction of these cells also coexpress DC-SIGN and CCR5, thus providing a cellular environment whereby the cis enhancement effect of DC-SIGN can come into play. It is interesting to note that alveolar macrophages have been proposed to be a reservoir in late stages of disease, because there is a significant increase of HIV-1 RNA in alveolar macrophages, but not monocytes from subjects with AIDS (32). Among HIV-positive asymptomatic subjects, HIV-1 was undetectable or at low levels in both blood monocytes and alveolar macrophages (32). Thus, whether progressive HIV disease (as a chronic inflammatory state) can lead to tissue microenvironments that favor DC-SIGN upregulation is a matter for future studies.
In addition to enhancing virus infection via the major coreceptors when expressed in cis, DC-SIGN also made infection via an alternate coreceptor more efficient. Although more than 10 chemokine receptors or 7TM GPCRs (other than CCR5 and CXCR4) have been reported to have coreceptor activity in vitro, some of these receptors are not expressed on CD4+ cell types in vivo, or are expressed at levels that do not support efficient infection, at least for most virus strains (reviewed in references 4, 9, and 10). The alternate coreceptor, STRL33, is an example of this. When overexpressed on cell lines, STRL33 can mediate efficient infection by a number of HIV-1, HIV-2, and SIV strains (11, 30). However, STRL33 expression in vivo is limited to only subsets of CD4+ T cells and NK cells (30, 38, 40), where on average less than 10,000 molecules are expressed at the cell surface (30). While comparable to CCR5 and CXCR4 expression, this level of STRL33 expression is below the threshold needed for most viruses to utilize this coreceptor (30). Our finding that DC-SIGN can allow usage of alternate coreceptors like STRL33 at expression levels that normally do not support viral entry raises the possibility that the panoply of coreceptors present on permissive cell populations in vivo can actually be used for entry if DC-SIGN was upregulated on the same cells. These findings may have implications for viral pathogenesis in vivo if conditions exist that can upregulate DC-SIGN, or perhaps other attachment factors, in certain tissue microenvironments. To this end, we found that only macrophages in certain tissues (e.g., lung and placenta) express DC-SIGN (Fig. 6A) (34), indicating that microenvironmental cues play a role in regulating the expression of DC-SIGN.
The precise mechanism by which DC-SIGN expression enhances infection in cis is unknown at present. However, the high affinity of DC-SIGN for HIV-1 Env suggests that DC-SIGN may serve to anchor the virion to the cell surface and thus increase the local concentration of viral particles at the plasma membrane. In situations where CD4 or coreceptor is limiting, this local concentration effect will likely increase the probability of the virion encountering its requisite entry factors. The colocalization of DC-SIGN with CD4 and CCR5 on the surface of alveolar macrophages suggests that the cis enhancement effect may be partially due to the ability of DC-SIGN to concentrate virions in physical proximity to its cognate receptors. Whether there are direct interactions between DC-SIGN and CD4 and CCR5, both of which are glycosylated, or whether these proteins partition into membrane microdomains remains to be determined.
In summary, our studies provide evidence that DC-SIGN can enhance infection in cis in addition to its reported trans infection properties. Our findings indicate that under some conditions, viral tropism can be modulated by a molecule other than a coreceptor. Since DC-SIGN is not commonly expressed on in vitro-cultured PBMCs and macrophages, studies of viral tropism with in vitro-cultured primary cells, which are at best a poor mimic of the complex microenvironmental milieu should be interpreted with some degree of caution. Whether the phenomenon of DC-SIGN cis enhancement plays a major role in the pathogenesis of HIV disease awaits confirmation by studying DC-SIGN expression in animal models and by the use of antibodies or other inhibitors of virus-DC-SIGN interactions.
| |
ACKNOWLEDGMENTS |
|---|
We acknowledge the support of the UCLA AIDS Institute and the flow cytometry core (UCLA CFAR grant, NIH AI-28697). B.L. is a recipient of the Burroughs Wellcome Fund Career Development Award and is supported by NIH grant HL 03923 and a Frontiers of Science Award from UCLA. E.S. is supported by a Medical Research Council Clinical Training Fellowship and by the Sackler Foundation. N.C. is supported by the Medical Research Council and the Cancer Research Campaign. M.H.M. is supported by NIH grant AI46942. U.O. is supported by NIH grant HL03984-L. R.W.D. is an Elizabeth Glaser Scientist supported by the Pediatrics AIDS Foundation and a recipient of the Burroughs Wellcome Fund Translational Research Award and is supported by NIH grant AI40880.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address for Benhur Lee: Department of Microbiology, Immunology & Molecular Genetics, UCLA, 3825 Molecular Sciences Building, 609 Charles E. Young Dr. East, Los Angeles, CA 90095-1489. Phone: (310) 794-2132. Fax: (310) 267-2580. E-mail: benhurL{at}microbio.ucla.edu. Mailing address for Robert W. Doms: Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, 36th and Hamilton Walk, Philadelphia, PA 19104. Phone: (215) 898-0890. Fax: (215) 898-9557. E-mail: doms{at}mail.med.upenn.edu.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
| 1. |
Baba, M.,
O. Nishimura,
N. Kanzaki,
M. Okamoto,
H. Sawada,
Y. Iizawa,
M. Shiraishi,
Y. Aramaki,
K. Okonogi,
Y. Ogawa,
K. Meguro, and M. Fujino.
1999.
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
Proc. Natl. Acad. Sci. USA
96:5698-5703 |
| 2. |
Bannert, N.,
D. Schenten,
S. Craig, and J. Sodroski.
2000.
The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses.
J. Virol.
74:10984-10993 |
| 2a. |
Baribaud, F.,
S. Pohlmann,
T. Sparwasser,
M. T. Kimata,
Y. K. Choi,
B. S. Haggarty,
N. Ahmad,
T. Macfarlan,
T. G. Edwards,
G. J. Leslie,
J. Arnason,
T. A. Reinhart,
J. T. Kimata,
D. R. Littman,
J. A. Hoxie, and R. W. Doms.
2001.
Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN.
J. Virol.
75:10281-10289 |
| 3. |
Bashirova, A. A.,
T. B. Geijtenbeek,
G. C. van Duijnhoven,
S. J. van Vliet,
J. B. Eilering,
M. P. Martin,
L. Wu,
T. D. Martin,
N. Viebig,
P. A. Knolle,
V. N. KewalRamani,
Y. van Kooyk, and M. Carrington.
2001.
A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection.
J. Exp. Med.
193:671-678 |
| 4. | Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700[CrossRef][Medline]. |
| 5. |
Boyd, M. T.,
G. R. Simpson,
A. J. Cann,
M. A. Johnson, and R. W. Weiss.
1993.
A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism.
J. Virol.
67:3649-3652 |
| 6. |
Curtis, B. M.,
S. Scharnowske, and A. J. Watson.
1992.
Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120.
Proc. Natl. Acad. Sci. USA
89:8356-8360 |
| 7. |
Dejucq, N.,
G. Simmons, and P. R. Clapham.
1999.
Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4+ T-cell lines determined by the capacity to exploit low concentrations of CCR5.
J. Virol.
73:7842-7847 |
| 8. | Doms, R. W. 2000. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276:229-237[CrossRef][Medline]. |
| 9. |
Doms, R. W., and D. Trono.
2000.
The plasma membrane as a combat zone in the HIV battlefield.
Genes Dev.
14:2677-2688 |
| 10. | Edinger, A. L., J. E. Clements, and R. W. Doms. 1999. Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Virology 260:211-221[CrossRef][Medline]. |
| 11. | Edinger, A. L., T. L. Hoffman, M. Sharron, B. Lee, B. O'Dowd, and R. W. Doms. 1998. Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 249:367-378[CrossRef][Medline]. |
| 12. | Fortin, J.-F., R. Cantin, G. Lamontagne, and M. Tremblay. 1997. Host-derived ICAM-1 glycoproteins is incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J. Virol. 5:3588-3596. |
| 13. | Geijtenbeek, T. B., D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, J. Middel, I. L. Cornelissen, H. S. Nottet, V. N. KewalRamani, D. R. Littman, C. G. Figdor, and Y. van Kooyk. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597[CrossRef][Medline]. |
| 14. | Geijtenbeek, T. B., R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, G. J. Adema, Y. van Kooyk, and C. G. Figdor. 2000. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100:575-585[CrossRef][Medline]. |
| 15. | Haugen, T. S., B. Nakstad, O. H. Skjonsberg, and T. Lyberg. 1998. CD14 expression and binding of lipopolysaccharide to alveolar macrophages and monocytes. Inflammation 22:521-532[CrossRef][Medline]. |
| 16. | Kesson, A. M., W. R. Fear, L. Williams, J. Chang, N. J. King, and A. L. Cunningham. 1994. HIV infection of placental macrophages: their potential role in vertical transmission. J. Leukoc. Biol. 56:241-246[Abstract]. |
| 17. | Lebargy, F., A. Branellec, L. Deforges, J. Bignon, and J. F. Bernaudin. 1994. HIV-1 in human alveolar macrophages from infected patients is latent in vivo but replicates after in vitro stimulation. Am. J. Respir. Cell. Mol. Biol. 10:72-78[Abstract]. |
| 18. |
Lee, B.,
M. Sharron,
L. J. Montaner,
D. Weissman, and R. W. Doms.
1999.
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages.
Proc. Natl. Acad. Sci. USA
96:5215-5220 |
| 19. | Lewin, S. R., S. Sonza, L. B. Irving, C. F. McDonald, J. Mills, and S. M. Crowe. 1996. Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. AIDS Res. Hum. Retroviruses 12:877-883[Medline]. |
| 20. | Martin, A. W., K. Brady, S. I. Smith, D. DeCoste, D. V. Page, A. Malpica, B. Wolf, and R. S. Neiman. 1992. Immunohistochemical localization of human immunodeficiency virus p24 antigen in placental tissue. Hum. Pathol. 23:411-414[CrossRef][Medline]. |
| 21. |
Mondor, I.,
S. Ugolini, and Q. J. Sattentau.
1998.
Human immunodeficiency virus type I attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.
J. Virol.
72:3623-3634 |
| 22. |
Mori, K.,
M. Rosenzweig, and R. C. Desrosiers.
2000.
Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages.
J. Virol.
74:10852-10859 |
| 23. |
O'Doherty, U.,
W. J. Swiggard, and M. H. Malim.
2000.
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.
J. Virol.
74:10074-10080 |
| 24. | Patel, M., M. Yanagishita, G. Roderiquez, D. C. Bou-Habib, T. Oravecz, V. C. Hascall, and M. A. Norcross. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruses 9:167-174[Medline]. |
| 25. | Plata, F., F. Garcia-Pons, A. Ryter, F. Lebargy, M. M. Goodenow, M. H. Dat, B. Autran, and C. Mayaud. 1990. HIV-1 infection of lung alveolar fibroblasts and macrophages in humans. AIDS Res. Hum. Retroviruses 6:979-986[Medline]. |
| 26. |
Platt, E. J.,
K. Wehrly,
S. E. Kuhnman,
B. Chesbro, and D. Kabat.
1998.
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage-tropic isolates of human immunodeficiency virus type 1.
J. Virol.
72:2855-2864 |
| 27. |
Pohlmann, S.,
F. Baribaud,
B. Lee,
G. J. Leslie,
M. D. Sanchez,
K. Hiebenthal-Millow,
J. Munch,
F. Kirchhoff, and R. W. Doms.
2001.
DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus.
J. Virol.
75:4664-4672 |
| 28. |
Pohlmann, S.,
E. J. Soilleux,
F. Baribaud,
G. J. Leslie,
L. S. Morris,
J. Trowsdale,
B. Lee,
N. Coleman, and R. W. Doms.
2001.
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans.
Proc. Natl. Acad. Sci. USA
98:2670-2675 |
| 29. | Roderiquez, G., T. Oravecz, M. Yanagishita, D. C. Bou-Habib, H. Mostowski, and M. A. Norcross. 1995. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J. Virol. 69:2233-2239[Abstract]. |
| 30. |
Sharron, M.,
S. Pohlmann,
K. Price,
E. Lolis,
M. Tsang,
F. Kirchhoff,
R. W. Doms, and B. Lee.
2000.
Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes.
Blood
96:41-49 |
| 31. | Sheikh, A. U., B. M. Polliotti, and R. K. Miller. 2000. Human immunodeficiency virus infection: in situ polymerase chain reaction localization in human placentas after in utero and in vitro infection. Am. J. Obstet. Gynecol. 182:207-213[CrossRef][Medline]. |
| 32. | Sierra-Madero, J. G., Z. Toossi, D. L. Hom, C. K. Finegan, E. Hoenig, and E. A. Rich. 1994. Relationship between load of virus in alveolar macrophages from human immunodeficiency virus type 1-infected persons, production of cytokines, and clinical status. J. Infect. Dis. 169:18-27[Medline]. |
| 33. |
Soilleux, E. J.,
R. Barten, and J. Trowsdale.
2000.
DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13.
J. Immunol.
165:2937-2942 |
| 34. | Soilleux, E. J., L. S. Morris, S. Poehlmann, B. Lee, R. W. Doms, J. Trowsdale, and N. Coleman. DC-SIGN expression analysis in the adult fetus and placenta: implications for the vertical transmission of HIV. J. Pathol., in press. |
| 35. | Steinman, R. M. 2000. DC-SIGN: a guide to some mysteries of dendritic cells. Cell 100:491-494[CrossRef][Medline]. |
| 36. |
Tominaga, Y.,
Y. Kita,
A. Satoh,
S. Asai,
K. Kato,
K. Ishikawa,
T. Horiuchi, and T. Takashi.
1998.
Affinity and kinetic analysis of the molecular interaction of ICAM-1 and leukocyte function-associated antigen-1.
J. Immunol.
161:4016-4022 |
| 37. | Ugolini, S., I. Mondor, and Q. J. Sattentau. 1999. HIV-1 attachment: another look. Trends Microbiol. 7:144-149[CrossRef][Medline]. |
| 38. |
Unutmaz, D.,
W. Xiang,
M. J. Sunshine,
J. Campbell,
E. Butcher, and D. R. Littman.
2000.
The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse.
J. Immunol.
165:3284-3292 |
| 39. | van Hal, P. T., J. M. Wijkhuijs, P. G. Mulder, and H. C. Hoogsteden. 1995. Proliferation of mature and immature subpopulations of bronchoalveolar monocytes/macrophages and peripheral blood monocytes. Cell Prolif. 28:533-543[Medline]. |
| 40. |
Wilbanks, A.,
S. C. Zondlo,
K. Murphy,
S. Mak,
D. Soler,
P. Langdon,
D. P. Andrew,
L. Wu, and M. Briskin.
2001.
Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines.
J. Immunol.
166:5145-5154 |
Journal of Virology, December 2001, p. 12028-12038, Vol. 75, No. 24
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.24.12028-12038.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Cannon, G., Yi, Y., Ni, H., Stoddard, E., Scales, D. A., Van Ryk, D. I., Chaiken, I., Malamud, D., Weissman, D.
(2008). HIV Envelope Binding by Macrophage-Expressed gp340 Promotes HIV-1 Infection. J. Immunol.
181: 2065-2070
[Abstract] [Full Text] -
Kawamura, T., Koyanagi, Y., Nakamura, Y., Ogawa, Y., Yamashita, A., Iwamoto, T., Ito, M., Blauvelt, A., Shimada, S.
(2008). Significant Virus Replication in Langerhans Cells following Application of HIV to Abraded Skin: Relevance to Occupational Transmission of HIV. J. Immunol.
180: 3297-3304
[Abstract] [Full Text] -
Serrano-Gomez, D., Sierra-Filardi, E., Martinez-Nunez, R. T., Caparros, E., Delgado, R., Munoz-Fernandez, M. A., Abad, M. A., Jimenez-Barbero, J., Leal, M., Corbi, A. L.
(2008). Structural Requirements for Multimerization of the Pathogen Receptor Dendritic Cell-specific ICAM3-grabbing Non-integrin (CD209) on the Cell Surface. J. Biol. Chem.
283: 3889-3903
[Abstract] [Full Text] -
de Witte, L., Bobardt, M., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T. B. H., Gallay, P.
(2007). Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. USA
104: 19464-19469
[Abstract] [Full Text] -
Hong, P. W.-P., Nguyen, S., Young, S., Su, S. V., Lee, B.
(2007). Identification of the Optimal DC-SIGN Binding Site on Human Immunodeficiency Virus Type 1 gp120. J. Virol.
81: 8325-8336
[Abstract] [Full Text] -
Wang, J.-H., Janas, A. M., Olson, W. J., KewalRamani, V. N., Wu, L.
(2007). CD4 Coexpression Regulates DC-SIGN-Mediated Transmission of Human Immunodeficiency Virus Type 1. J. Virol.
81: 2497-2507
[Abstract] [Full Text] -
Boggiano, C., Manel, N., Littman, D. R.
(2007). Dendritic Cell-Mediated trans-Enhancement of Human Immunodeficiency Virus Type 1 Infectivity Is Independent of DC-SIGN. J. Virol.
81: 2519-2523
[Abstract] [Full Text] -
Gilbert, C., Barat, C., Cantin, R., Tremblay, M. J.
(2007). Involvement of Src and Syk Tyrosine Kinases in HIV-1 Transfer from Dendritic Cells to CD4+ T Lymphocytes. J. Immunol.
178: 2862-2871
[Abstract] [Full Text] -
Davis, C. W., Mattei, L. M., Nguyen, H.-Y., Ansarah-Sobrinho, C., Doms, R. W., Pierson, T. C.
(2006). The Location of Asparagine-linked Glycans on West Nile Virions Controls Their Interactions with CD209 (Dendritic Cell-specific ICAM-3 Grabbing Nonintegrin). J. Biol. Chem.
281: 37183-37194
[Abstract] [Full Text] -
Donaghy, H., Wilkinson, J., Cunningham, A. L.
(2006). HIV interactions with dendritic cells: has our focus been too narrow?. J. Leukoc. Biol.
80: 1001-1012
[Abstract] [Full Text] -
Falkowska, E., Durso, R. J., Gardner, J. P., Cormier, E. G., Arrigale, R. A., Ogawa, R. N., Donovan, G. P., Maddon, P. J., Olson, W. C., Dragic, T.
(2006). L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles. J. Gen. Virol.
87: 2571-2576
[Abstract] [Full Text] -
Moris, A., Pajot, A., Blanchet, F., Guivel-Benhassine, F., Salcedo, M., Schwartz, O.
(2006). Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer. Blood
108: 1643-1651
[Abstract] [Full Text] -
Lai, W. K., Sun, P. J., Zhang, J., Jennings, A., Lalor, P. F., Hubscher, S., McKeating, J. A., Adams, D. H.
(2006). Expression of DC-SIGN and DC-SIGNR on Human Sinusoidal Endothelium: A Role for Capturing Hepatitis C Virus Particles. Am. J. Pathol.
169: 200-208
[Abstract] [Full Text] -
Burleigh, L., Lozach, P.-Y., Schiffer, C., Staropoli, I., Pezo, V., Porrot, F., Canque, B., Virelizier, J.-L., Arenzana-Seisdedos, F., Amara, A.
(2006). Infection of Dendritic Cells (DCs), Not DC-SIGN-Mediated Internalization of Human Immunodeficiency Virus, Is Required for Long-Term Transfer of Virus to T Cells. J. Virol.
80: 2949-2957
[Abstract] [Full Text] -
Cavrois, M., Neidleman, J., Kreisberg, J. F., Fenard, D., Callebaut, C., Greene, W. C.
(2006). Human Immunodeficiency Virus Fusion to Dendritic Cells Declines as Cells Mature. J. Virol.
80: 1992-1999
[Abstract] [Full Text] -
Davis, C. W., Nguyen, H.-Y., Hanna, S. L., Sanchez, M. D., Doms, R. W., Pierson, T. C.
(2006). West Nile Virus Discriminates between DC-SIGN and DC-SIGNR for Cellular Attachment and Infection. J. Virol.
80: 1290-1301
[Abstract] [Full Text] -
Triantis, V., Trancikova, D. E., Looman, M. W. G., Hartgers, F. C., Janssen, R. A. J., Adema, G. J.
(2006). Identification and Characterization of DC-SCRIPT, a Novel Dendritic Cell-Expressed Member of the Zinc Finger Family of Transcriptional Regulators. J. Immunol.
176: 1081-1089
[Abstract] [Full Text] -
Granelli-Piperno, A., Pritsker, A., Pack, M., Shimeliovich, I., Arrighi, J.-F., Park, C. G., Trumpfheller, C., Piguet, V., Moran, T. M., Steinman, R. M.
(2005). Dendritic Cell-Specific Intercellular Adhesion Molecule 3-Grabbing Nonintegrin/CD209 Is Abundant on Macrophages in the Normal Human Lymph Node and Is Not Required for Dendritic Cell Stimulation of the Mixed Leukocyte Reaction. J. Immunol.
175: 4265-4273
[Abstract] [Full Text] -
VanCompernolle, S. E., Taylor, R. J., Oswald-Richter, K., Jiang, J., Youree, B. E., Bowie, J. H., Tyler, M. J., Conlon, J. M., Wade, D., Aiken, C., Dermody, T. S., KewalRamani, V. N., Rollins-Smith, L. A., Unutmaz, D.
(2005). Antimicrobial Peptides from Amphibian Skin Potently Inhibit Human Immunodeficiency Virus Infection and Transfer of Virus from Dendritic Cells to T Cells. J. Virol.
79: 11598-11606
[Abstract] [Full Text] -
Bernhard, O. K., Lai, J., Wilkinson, J., Sheil, M. M., Cunningham, A. L.
(2004). Proteomic Analysis of DC-SIGN on Dendritic Cells Detects Tetramers Required for Ligand Binding but No Association with CD4. J. Biol. Chem.
279: 51828-51835
[Abstract] [Full Text] -
Su, S. V., Hong, P., Baik, S., Negrete, O. A., Gurney, K. B., Lee, B.
(2004). DC-SIGN Binds to HIV-1 Glycoprotein 120 in a Distinct but Overlapping Fashion Compared with ICAM-2 and ICAM-3. J. Biol. Chem.
279: 19122-19132
[Abstract] [Full Text] -
Moris, A., Nobile, C., Buseyne, F., Porrot, F., Abastado, J.-P., Schwartz, O.
(2004). DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood
103: 2648-2654
[Abstract] [Full Text] -
Takada, A., Fujioka, K., Tsuiji, M., Morikawa, A., Higashi, N., Ebihara, H., Kobasa, D., Feldmann, H., Irimura, T., Kawaoka, Y.
(2004). Human Macrophage C-Type Lectin Specific for Galactose and N-Acetylgalactosamine Promotes Filovirus Entry. J. Virol.
78: 2943-2947
[Abstract] [Full Text] -
Turville, S. G., Santos, J. J., Frank, I., Cameron, P. U., Wilkinson, J., Miranda-Saksena, M., Dable, J., Stossel, H., Romani, N., Piatak, M. Jr, Lifson, J. D., Pope, M., Cunningham, A. L.
(2004). Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood
103: 2170-2179
[Abstract] [Full Text] -
de Parseval, A., Su, S. V., Elder, J. H., Lee, B.
(2004). Specific Interaction of Feline Immunodeficiency Virus Surface Glycoprotein with Human DC-SIGN. J. Virol.
78: 2597-2600
[Abstract] [Full Text] -
Ploquin, M. J.-Y., Diop, O. M., Sol-Foulon, N., Mortara, L., Faye, A., Soares, M. A., Nerrienet, E., Le Grand, R., Van Kooyk, Y., Amara, A., Schwartz, O., Barre-Sinoussi, F., Muller-Trutwin, M. C.
(2004). DC-SIGN from African Green Monkeys Is Expressed in Lymph Nodes and Mediates Infection in trans of Simian Immunodeficiency Virus SIVagm. J. Virol.
78: 798-810
[Abstract] [Full Text] -
Soilleux, E J, Coleman, N
(2004). Expression of DC-SIGN in human foreskin may facilitate sexual transmission of HIV. J. Clin. Pathol.
57: 77-78
[Abstract] [Full Text] -
Turville, S., Wilkinson, J., Cameron, P., Dable, J., Cunningham, A. L.
(2003). The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J. Leukoc. Biol.
74: 710-718
[Abstract] [Full Text] -
Kawamura, T., Gulden, F. O., Sugaya, M., McNamara, D. T., Borris, D. L., Lederman, M. M., Orenstein, J. M., Zimmerman, P. A., Blauvelt, A.
(2003). R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc. Natl. Acad. Sci. USA
100: 8401-8406
[Abstract] [Full Text] -
Nobile, C., Moris, A., Porrot, F., Sol-Foulon, N., Schwartz, O.
(2003). Inhibition of Human Immunodeficiency Virus Type 1 Env-Mediated Fusion by DC-SIGN. J. Virol.
77: 5313-5323
[Abstract] [Full Text] -
Gardner, J. P., Durso, R. J., Arrigale, R. R., Donovan, G. P., Maddon, P. J., Dragic, T., Olson, W. C.
(2003). L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl. Acad. Sci. USA
100: 4498-4503
[Abstract] [Full Text] -
Tassaneetrithep, B., Burgess, T. H., Granelli-Piperno, A., Trumpfheller, C., Finke, J., Sun, W., Eller, M. A., Pattanapanyasat, K., Sarasombath, S., Birx, D. L., Steinman, R. M., Schlesinger, S., Marovich, M. A.
(2003). DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells. JEM
197: 823-829
[Abstract] [Full Text] -
Pohlmann, S., Zhang, J., Baribaud, F., Chen, Z., Leslie, G. J., Lin, G., Granelli-Piperno, A., Doms, R. W., Rice, C. M., McKeating, J. A.
(2003). Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR. J. Virol.
77: 4070-4080
[Abstract] [Full Text] -
Maeda, N., Nigou, J., Herrmann, J.-L., Jackson, M., Amara, A., Lagrange, P. H., Puzo, G., Gicquel, B., Neyrolles, O.
(2003). The Cell Surface Receptor DC-SIGN Discriminates between Mycobacterium Species through Selective Recognition of the Mannose Caps on Lipoarabinomannan. J. Biol. Chem.
278: 5513-5516
[Abstract] [Full Text] -
Trumpfheller, C., Park, C. G., Finke, J., Steinman, R. M., Granelli-Piperno, A.
(2003). Cell type-dependent retention and transmission of HIV-1 by DC-SIGN. Int Immunol
15: 289-298
[Abstract] [Full Text] -
Tailleux, L., Schwartz, O., Herrmann, J.-L., Pivert, E., Jackson, M., Amara, A., Legres, L., Dreher, D., Nicod, L. P., Gluckman, J. C., Lagrange, P. H., Gicquel, B., Neyrolles, O.
(2003). DC-SIGN Is the Major Mycobacterium tuberculosis Receptor on Human Dendritic Cells. JEM
197: 121-127
[Abstract] [Full Text] -
Lin, G., Baribaud, F., Romano, J., Doms, R. W., Hoxie, J. A.
(2002). Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins. J. Virol.
77: 931-942
[Abstract] [Full Text] -
Lin, G., Simmons, G., Pohlmann, S., Baribaud, F., Ni, H., Leslie, G. J., Haggarty, B. S., Bates, P., Weissman, D., Hoxie, J. A., Doms, R. W.
(2002). Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR. J. Virol.
77: 1337-1346
[Abstract] [Full Text] -
Hong, P. W.-P., Flummerfelt, K. B., de Parseval, A., Gurney, K., Elder, J. H., Lee, B.
(2002). Human Immunodeficiency Virus Envelope (gp120) Binding to DC-SIGN and Primary Dendritic Cells Is Carbohydrate Dependent but Does Not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding. J. Virol.
76: 12855-12865
[Abstract] [Full Text] -
Yu Kimata, M. T., Cella, M., Biggins, J. E., Rorex, C., White, R., Hicks, S., Wilson, J. M., Patel, P. G., Allan, J. S., Colonna, M., Kimata, J. T.
(2002). Capture and Transfer of Simian Immunodeficiency Virus by Macaque Dendritic Cells Is Enhanced by DC-SIGN. J. Virol.
76: 11827-11836
[Abstract] [Full Text] -
Fuller, C. L., Choi, Y. K., Fallert, B. A., Capuano, S. III, Rajakumar, P., Murphey-Corb, M., Reinhart, T. A.
(2002). Restricted SIV Replication in Rhesus Macaque Lung Tissues During the Acute Phase of Infection. Am. J. Pathol.
161: 969-978
[Abstract] [Full Text] -
Baribaud, F., Pohlmann, S., Leslie, G., Mortari, F., Doms, R. W.
(2002). Quantitative Expression and Virus Transmission Analysis of DC-SIGN on Monocyte-Derived Dendritic Cells. J. Virol.
76: 9135-9142
[Abstract] [Full Text] -
Alvarez, C. P., Lasala, F., Carrillo, J., Muniz, O., Corbi, A. L., Delgado, R.
(2002). C-Type Lectins DC-SIGN and L-SIGN Mediate Cellular Entry by Ebola Virus in cis and in trans. J. Virol.
76: 6841-6844
[Abstract] [Full Text] -
Geijtenbeek, T. B. H., Engering, A., van Kooyk, Y.
(2002). DC-SIGN, a C-type lectin on dendritic cells that unveils many aspects of dendritic cell biology. J. Leukoc. Biol.
71: 921-931
[Abstract] [Full Text] -
Wu, L., Martin, T. D., Vazeux, R., Unutmaz, D., KewalRamani, V. N.
(2002). Functional Evaluation of DC-SIGN Monoclonal Antibodies Reveals DC-SIGN Interactions with ICAM-3 Do Not Promote Human Immunodeficiency Virus Type 1 Transmission. J. Virol.
76: 5905-5914
[Abstract] [Full Text] -
Soilleux, E. J., Morris, L. S., Leslie, G., Chehimi, J., Luo, Q., Levroney, E., Trowsdale, J., Montaner, L. J., Doms, R. W., Weissman, D., Coleman, N., Lee, B.
(2002). Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J. Leukoc. Biol.
71: 445-457
[Abstract] [Full Text] -
Frank, I., Piatak, M. Jr., Stoessel, H., Romani, N., Bonnyay, D., Lifson, J.D., Pope, M.
(2002). Infectious and Whole Inactivated Simian Immunodeficiency Viruses Interact Similarly with Primate Dendritic Cells (DCs): Differential Intracellular Fate of Virions in Mature and Immature DCs. J. Virol.
76: 2936-2951
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»